You are here: Industry Insights > Sintilimab

News List

Innovent's PD-1 suffered setbacks in the listing of overseas market, a paradigm for Chinese innovative drug in the global market PharmaSources/Caicai
February 22, 2022
Recently, FDA held an ODAC (Oncologic Drugs Advisory Committee) meeting around the key event in the listing application of Sintilimab, Innovent's PD-1 monoclonal antibody, in the United States.
In 2021, the sales volume of Innovent's PD-1 exceeded RMB 3 billion PharmaSources/Caicai
February 21, 2022
Chinese PD-1 also sells well. According to the quarterly sales data of Innovent's sintilimab (trade name: Tyvyt), its sales volume was about RMB 3.1 billion in 2021 (nominal sales revenue).
China's First Domestic CTLA-4 Inhibitor, in Combination With Sintilimab as Neoadjuvant Treatment for Colon Cancer PR Newswire
February 24, 2025
NMPA Accepts NDA and Grants Priority Review Designation to combine with Sintilimab as Treatment for Colon Cancer.
Innovent and Eli Lilly announce final clinical results and biomarker analysis of phase-Ib study of Sintilimab injection plus Bevacizumab biosimilar injection ExpressPharma
January 24, 2022
The Overall Response Rate (ORR) was 34 per cent (17/50) and ORRs for the low-dose and high-dose groups were 31 per cent and 38 per cent, respectively...
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal prnasia
November 05, 2021
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer...
Innovent and NeoCura Announce Strategic Collaboration to Study the Combination Therapy of Sintilimab and Neoantigen Vaccine NEO_PLIN2101 for Cancer Treatment in China prnasia
October 28, 2021
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic...
Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint prnasia
October 18, 2021
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology
Updated Overall Survival Data and Biomarker Results from Sintilimab ORIENT-11 Study in First-Line Nonsquamous Non-Small Cell Lung Cancer Published in the Journal of Thoracic Oncology prnasia
August 06, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, and Eli Lilly and Company today ...
Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib in Clinical Studies in China prnasia
July 06, 2021
Innovent and Laekna today jointly announced they have entered into a collaboration agreement to evaluate the combination of Innovent's PD-1 inhibitor sintilimab and Laekna's pan-AKT kinase inhibitor afuresertib.
Sintilimab in Combination with Chemotherapy Meets Overall Survival Primary Endpoint in the Global Phase 3 ORIENT-15 Study for the First-Line Treatment of Esophageal Squamous Cell Carcinoma prnasia
June 23, 2021
Innovent Biologics, Inc. today announced that the Phase 3 ORIENT-15 study met the predefined overall survival primary endpoint.

Previous page 1 2 Next page